Impact of correction of anemia on major complication of chronic renal diseases
Eleven uraemic predialysis patients have been selected for the treatment of anaemia with rhuEPO. Administration of rhuEPO was followed by a significant increase of the Hct value and haemoglobin concentration as well as an improvement of well being. The main adverse effects of rhuEPO therapy were the following: increase of blood pressure, reduction of the residual renal function and increase of serum potassium and phosphorous concentration. Monitoring of the iron status in uraemic predialysis patients on rhuEPO therapy seems to be mandatory.